Adults 60 to 85, any sex, with Metabolism or Protein. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Whole Body Net Balance Measured by Gas Chromatography-Mass Spectrometry (GC-MS)Primary· 300 minutes
Blood samples were analyzed to quantify the appearance of the stable isotopes: 2H2-tyrosine, 2H4-tyrosine, and 2H5-phenylalanine in tracer to tracee ratio or mole percent excess. Changes in these markers over time enable the calculation of whole body protein metabolism. Calculations are done as follows:
Total plasma rate of appearance = infusion rate/enrichment Fractional rate of appearance of tyrosine from phenylalanine= 2H4-tyrosine/2H5-phenylalanine Phenylalanine hydroxylation = fractional rate of appearance of tyrosine from phenylalanine x rate of appearance of tyrosine Protein Synthesis
Group
Value
95% CI
Gold Kiwifruit
14.58
± 4.31
Green Hayward Kiwifruit
14.55
± 3.24
Change in Skeletal Muscle Protein Metabolism Measured by Gas Chromatography-Mass Spectrometry (GC-MS)Secondary· 9.5 hours
Muscle samples were analyzed to quantify the appearance of the stable isotope 2H5-phenylalanine in trace to tracee ratio or mole percent excess. The change in 2H5-phenylalanine in subsequent muscle biopsy allow for the calculation of muscle protein synthesis. The calculation is done as follows: \[(2H5-phenylalanine enrichment in second biopsy - 2H5-phenylalanine enrichment in second biopsy)/ (2H5-phenylalanine plasma enrichment × time)\] × 60 × 100.
Group
Value
95% CI
Gold Kiwifruit
0.0043
± 0.0244
Green Hayward Kiwifruit
0.0081
± 0.0393
Adverse events — posted to ClinicalTrials.gov
Time frame: While subjects were enrolled in the study; up to two months..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The specific hypothesis is that the consumption of 2 Hayward green kiwifruit (containing actinidin protease) prior to 100g of ground beef will increase the rate of protein digestion from the beef in the elderly, leading to an increased uptake of the essential amino acids. Furthermore, this increased essential amino acid availability will produce a greater postprandial net anabolic protein response, as well as increased fractional synthetic rates of muscle proteins.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06930976 — Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells
· NA
· recruiting
NCT07141537 — Caloric Balance Markers Study
· recruiting
NCT06907329 — The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and
· NA
· recruiting
NCT06813261 — GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women
· NA
· recruiting
NCT06754709 — Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children
· recruiting
Other University of Arkansas trials
Trials by the same sponsor.
NCT07029776 — MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
· Phase 2
· not yet recruiting
NCT07341399 — Essential Amino Acid Supplementation in Adult Spinal Deformity Patients
· NA
· not yet recruiting
NCT07071766 — Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment
· NA
· recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arkansas
Last refreshed: 4 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04356573.